Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997166 | 1.00 | EIF2AK4 (0.48) | EIF2AK4ADORA2A | |
| SCHEMBL1996002 | 0.93 | EIF2AK4 (0.47) | EIF2AK4 | |
| SCHEMBL1993019 | 0.90 | EIF2AK4 (0.50) | EIF2AK4 | |
| SCHEMBL1993022 | 0.90 | EIF2AK4 (0.50) | EIF2AK4 | |
| SCHEMBL1993296 | 0.87 | EIF2AK4 (0.46) | EIF2AK4 | |
| SCHEMBL12643818 | 0.87 | EIF2AK4 (0.43) | EIF2AK4ADORA2A | |
| SCHEMBL1996140 | 0.85 | EIF2AK4 (0.42) | EIF2AK4ADORA2A | |
| SCHEMBL2032642 | 0.81 | EIF2AK4 (0.46) | EIF2AK4ADORA2A | |
| SCHEMBL2000295 | 0.80 | EIF2AK4 (0.47) | EIF2AK4 | |
| SCHEMBL2000293 | 0.80 | EIF2AK4 (0.47) | EIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | EIF2AK4 211/4885ADORA2A 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.